Medication info
Biltaport Tablet 50 mg (Vildagliptin)

Biltaport Tablet 50 mg (Vildagliptin)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
White to pale yellow round tablet
Packaging
30 tablets/box [(10 tablets/Alu-Alu*3)]
Approval status
Active

MFDS item code 202101878 · Approved 2021.02.25 · Insurance code 671706860

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
When used as monotherapy or in combination with metformin in patients with no prior antidiabetic drug treatment, administer 50mg once daily in the morning or 100mg daily as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with metformin or a thiazolidinedione alone, the recommended dose of this medicine in combination with metformin or a thiazolidinedione is 100mg daily, given as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with a sulfonylurea alone, the recommended dose of this medicine in combination with a sulfonylurea is 50mg once daily in the morning. In this patient population, vildagliptin 100mg once daily was not more effective than 50mg once daily. When adequate glycemic control cannot be achieved with a sulfonylurea and metformin combination, the recommended dose of this medicine as add-on therapy (third-line therapy) is 100mg daily, given as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with insulin (insulin alone or in combination with metformin), the recommended dose of this medicine as add-on therapy is 100mg daily, given as 50mg twice daily, in the morning and evening. This medicine may be taken with or without food. Doses above 100mg daily are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember, and take the next dose at the usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take double the dose at one time to make up for a missed dose. This medicine is not recommended for patients with hepatic impairment whose ALT or AST level before treatment exceeds 2.5 times the upper limit of normal. Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. Moderate or severe renal impairment, or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood glucose control problems in patients with type 2 diabetes
View approved original text

This medication is used to assist in controlling blood glucose levels in patients with type 2 diabetes in conjunction with dietary management and exercise. It can be used alone or in combination with other medications to enhance therapeutic effects. Improved blood glucose management with this medication can help maintain a healthy lifestyle.

How to take

Adult dose

When used as monotherapy or in combination with metformin in patients with no prior antidiabetic drug treatment, administer 50mg once daily in the morning or 100mg daily as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with metformin or a thiazolidinedione alone, the recommended dose of this medicine in combination with metformin or a thiazolidinedione is 100mg daily, given as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with a sulfonylurea alone, the recommended dose of this medicine in combination with a sulfonylurea is 50mg once daily in the morning. In this patient population, vildagliptin 100mg once daily was not more effective than 50mg once daily. When adequate glycemic control cannot be achieved with a sulfonylurea and metformin combination, the recommended dose of this medicine as add-on therapy (third-line therapy) is 100mg daily, given as 50mg twice daily, in the morning and evening. When adequate glycemic control cannot be achieved with insulin (insulin alone or in combination with metformin), the recommended dose of this medicine as add-on therapy is 100mg daily, given as 50mg twice daily, in the morning and evening. This medicine may be taken with or without food. Doses above 100mg daily are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember, and take the next dose at the usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take double the dose at one time to make up for a missed dose. This medicine is not recommended for patients with hepatic impairment whose ALT or AST level before treatment exceeds 2.5 times the upper limit of normal. Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. Moderate or severe renal impairment, or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended.

Precautions

This medication should not be used by individuals who are allergic to its active ingredient or other components. Additionally, it should not be administered to patients with type 1 diabetes or those with diabetic ketoacidosis. Since this medication contains lactose, patients with genetic issues such as lactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it. While taking this medication, liver function abnormalities may rarely occur, so it's important to receive regular liver function tests. If liver function test results rise above three times the normal upper limit, the medication should be discontinued, and if symptoms of liver disease arise, consult a physician immediately. This medication does not replace insulin, so patients needing insulin therapy should continue their insulin treatments. The use of this medication is not recommended for patients with heart failure, especially those with severe cases. Abnormal symptoms such as skin blisters or ulcers may occur, so report any such symptoms to medical personnel immediately. There is a risk of acute pancreatitis, so if symptoms of pancreatitis are suspected, the medication should be discontinued immediately, and a doctor should be consulted. When taking this medication with other diabetes drugs that can cause hypoglycemia, there may be an increased risk of hypoglycemia, so caution is warranted. Symptoms such as dizziness or headaches may occur, so be careful when driving or operating machinery. It is safer not to use this medication for pregnant or breastfeeding women. This medication is not recommended for children or adolescents under 18 years of age. In case of overdose, there is no specific antidote, and supportive care may be required based on the symptoms. This medication is not removed by hemodialysis. Store this medication out of reach of children, and avoid transferring it to other containers.

Side effects

  • Hepatitis
  • liver dysfunction
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
  • nausea
  • hypoglycemia
  • rhinopharyngitis
Show 53 more
  • weakness
  • constipation
  • weight gain
  • peripheral edema
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decreased blood sugar
  • hyperhidrosis
  • pancreatitis
  • urticaria
  • blisters
  • desquamative skin lesions
  • severe arthralgia
  • vasculitis
  • cholecystitis
  • upper respiratory tract infection
  • upper respiratory tract infection
  • pruritus
  • dry mouth
  • vomiting
  • insomnia
  • dyspepsia
  • renal impairment
  • lip blister
  • drowsiness
  • chest discomfort
  • hunger
  • sensory impairment
  • spinal stenosis
  • abdominal pain
  • gastroenteritis
  • gastritis
  • gastric ulcer
  • belching
  • appendicitis
  • fatty liver
  • hyperkalemia
  • hypertriglyceridemia
  • heart failure
  • cardiomegaly
  • angina
  • cardiac arrest
  • renal cyst
  • lung carcinoma
  • leg pain
  • elevated C-reactive protein
  • myalgia
  • paresthesia
  • fever
  • edema
  • swelling of hands and feet

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

White to pale yellow round tablet

Package unit

30 tablets/box [(10 tablets/Alu-Alu*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.